Cargando…

Effectiveness and cost-effectiveness of prognostic markers in prostate cancer

This paper demonstrates how economic modelling can be used to derive estimates of the cost-effectiveness of prognostic markers in the management of clinically localised and moderately graded prostate cancer. The model uses a Markov process and is populated using published evidence and local data. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calvert, N W, Morgan, A B, Catto, J W F, Hamdy, F C, Akehurst, R L, Mouncey, P, Paisley, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376796/ https://www.ncbi.nlm.nih.gov/pubmed/12556955 http://dx.doi.org/10.1038/sj.bjc.6600630

Ejemplares similares

Markers for Detection of Prostate Cancer
por: Clarke, Raymond A., et al.
Publicado: (2010)

S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors
por: Rehman, I, et al.
Publicado: (2004)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study.
por: Naguib, R. N., et al.
Publicado: (1998)

Changes in circulating microRNA levels associated with prostate cancer
por: Bryant, R J, et al.
Publicado: (2012)

Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin
por: Reddy, Vivek Y., et al.
Publicado: (2016)

Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies
por: Pang, Karl H., et al.
Publicado: (2017)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
por: Catto, J W F, et al.
Publicado: (2011)

Cost-Effectiveness of the Use of Gold Anchor™ Markers in Prostate Cancer
por: Lundqvist, Martina, et al.
Publicado: (2020)

The Urinary Sarcosine/Creatinine Ratio is a Potential Diagnostic and Prognostic Marker in Prostate Cancer
por: Wang, Meng, et al.
Publicado: (2018)

Prognostic DNA Methylation Markers for Prostate Cancer
por: Strand, Siri H., et al.
Publicado: (2014)

The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
por: Noble, Sian M., et al.
Publicado: (2020)

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
por: Atherly, A J, et al.
Publicado: (2012)

Prognostic marker and target in prostate cancer
por: Lavorgna, Giovanni, et al.
Publicado: (2015)

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
por: Heijnsdijk, E A M, et al.
Publicado: (2009)

The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening
por: de Kok, I M C M, et al.
Publicado: (2009)

Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk
por: Hung, S-C, et al.
Publicado: (2013)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
por: Rosario, Derek J, et al.
Publicado: (2012)

BPH and prostate cancer risk
por: Miah, Saiful, et al.
Publicado: (2014)

Cost effectiveness of prostate cancer radiotherapy
por: Konski, Andre
Publicado: (2018)

An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer
por: Miah, S, et al.
Publicado: (2012)

Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer.
por: Jørgensen, T., et al.
Publicado: (1995)

Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer
por: Lin, Ying-Li, et al.
Publicado: (2017)

FDG–PET. A possible prognostic factor in head and neck cancer
por: Halfpenny, W, et al.
Publicado: (2002)

Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer
por: Dixon, Simon, et al.
Publicado: (2023)

Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study
por: Eschwège, P, et al.
Publicado: (2009)

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result
por: Macefield, R C, et al.
Publicado: (2010)

Integrated Analysis Revealed Prognostic Factors for Prostate Cancer Patients
por: Che, Hong, et al.
Publicado: (2019)

Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review
por: Hoogland, A. Marije, et al.
Publicado: (2014)

Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer
por: Roy, Soumyajit, et al.
Publicado: (2023)

Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data
por: Reddy, Vivek Y., et al.
Publicado: (2019)

The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism
por: Bessey, Alice, et al.
Publicado: (2020)

MUC1 as a Putative Prognostic Marker for Prostate Cancer
por: Strawbridge, Rona J, et al.
Publicado: (2008)

Mast Cells as a Potential Prognostic Marker in Prostate Cancer
por: Taverna, Gianluigi, et al.
Publicado: (2013)

Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer
por: Burdelski, Christoph, et al.
Publicado: (2014)

Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence
por: Fu, Min, et al.
Publicado: (2021)

Dickkopf-1 Expression Is a Novel Prognostic Marker for Gastric Cancer
por: Gao, Chengcheng, et al.
Publicado: (2012)

Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer
por: Bertorelle, R, et al.
Publicado: (2013)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
por: Cappuccini, Federica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_28gfhg376rgnobs0ue766ubv7j